UMHAT Sofiamed OOD
- Address
- Bulevard D-R G.m.dimitrov 16, 1797 Sofia, Bulgaria
Cardiovascular Diseases
At UMHAT Sofiamed OOD in Sofia, clinical research in Cardiovascular Diseases focuses on Acute Coronary Syndrome and recovery after heart attack, with studies aimed at reducing the risk of major heart and stroke-related events.
- Testing a new therapy to lower recurrent cardiovascular events after acute heart injury
- Evaluating whether treatment can better prevent cardiovascular death, heart attack, and ischemic stroke
These trials are designed to improve treatment effectiveness for patients already receiving standard care, with the goal of strengthening long-term protection against serious complications.
Musculoskeletal Diseases
The site also supports research in Musculoskeletal Diseases, centered on axial spondyloarthritis, a chronic inflammatory condition that can cause pain and stiffness in the spine and joints.
- Assessing a treatment intended to improve signs and symptoms of active disease
- Comparing how well a therapy works for reducing inflammation-related discomfort and functional burden
This area of research reflects a focus on better symptom control and improved daily functioning for people living with persistent rheumatic disease.
Neoplasms
In Neoplasms, UMHAT Sofiamed OOD is involved in studies for Extensive Stage Small Cell Lung Cancer and c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer, both of which are serious lung cancers with limited treatment options.
- Testing whether a supportive cancer therapy can help improve overall survival in advanced small cell lung cancer
- Evaluating a targeted treatment against a standard chemotherapy option in previously treated non-small cell lung cancer
These oncology trials aim to improve survival outcomes and explore more effective approaches for patients with difficult-to-treat lung malignancies.
Respiratory Tract Diseases
Research in Respiratory Tract Diseases at the Sofia-based hospital overlaps with advanced lung cancer studies, especially conditions affecting the lungs and airways.
- Studying new ways to manage lung cancer in patients whose disease has progressed after earlier treatment
- Comparing treatment effectiveness for advanced respiratory cancers to support better disease control
Overall, this work is centered on finding more effective options for serious pulmonary disease while helping refine care for patients with advanced cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in UMHAT Sofiamed OOD
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis | Alfasigma S.p.A. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-11-21 | 2023-11-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.